Vaccine | Preterm cohort | Preterm historical cohort | p | ||
---|---|---|---|---|---|
n/N | % (95%CI) | n/N | % (95%CI) | ||
DTaP-IPV-HBV-Hib 1 doses | 169/170 | 99.4 (96.3–100.0) | 156/159 | 98.1 (94.6–99.6) | 0.568 |
DTaP-IPV-HBV-Hib 2 doses | 165/168 | 98.2 (94.5–99.5) | 145/159 | 91.2 (85.7–95.1) | 0.009 |
DTaP-IPV-HBV-Hib 3 doses | 161/167 | 96.4 (92.0–98.5) | 138/158 | 87.3 (81.1–92.1) | 0.005 |
PCV 1 doses | 167/170 | 98.2 (94.7–99.5) | 157/159 | 98.7 (95.5–99.8) | > 0.99 |
PCV 2 doses | 160/168 | 95.2 (90.5–97.8) | 144/159 | 90.6 (84.9–94.6) | 0.151 |
PCV 3 doses | 152/167 | 91.0 (85.4–94.7) | 136/158 | 86.1 (79.7–91.1) | 0.220 |
Men C | 137/167 | 82.0 (75.2–87.4) | 135/157 | 86.0 (79.6–91.0) | 0.414 |
MMR | 158/167 | 94.6 (89.7–97.3) | 120/157 | 76.4 (69.0–82.8) | < 0.001 |
Varicella | 158/167 | 94.6 (89.7–97.3) | 127/157 | 80.9 (73.9–86.7) | < 0.001 |